Inventiva Announces the Screening of the First Patient in LEGEND, a Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva announced the screening in the US of the first patient in its LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with non-alcoholic steatohepatitis (NASH) and type 2 diabetes (T2D).